| ¿µ¹® | fetal monitoring | ÇÑ±Û | žư¨½Ã |
|---|---|---|---|
| ¼³¸í | ÀӽŠÁßÀ̳ª ºÐ¸¸ ÁßÀÇ Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ» žư¨½Ã¶ó°í ÇÑ´Ù. ¿©±â¿¡´Â ¿©·¯ °¡Áö ¹æ¹ýÀÌ Àִµ¥ Å©°Ô ºÐ¸¸Àü žư¨½Ã¿Í ºÐ¸¸Áß Å¾ư¨½Ã·Î Å©°Ô ³ª´«´Ù. 1. ºÐ¸¸Àü žư¨½Ã´Â ºÐ¸¸Çϱâ ÀÌÀüÀÇ Å¾ÆÀÇ »óŸ¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î ´ÙÀ½°ú °°Àº ¿©·¯ °¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. 1)¾ç¼öõÀÚ-ÁÖ»ç±â¸¦ ÀÌ¿ëÇØ¼ »ê¸ðÀÇ ¹è¸¦ ÅëÇØ¼ ¾ç¼ö¸¦ ¾ò¾î¼ ºÐ¼®ÇÏ¿© žÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â ¹æ¹ý. ÀӽŠ15ÁÖ À̻󿡼 ½Ç½ÃÇÒ ¼ö°¡ ÀÖ´Ù. 2)ÅÈÁÙõÀÚ-ÃÊÀ½ÆÄ°Ë»ç¸¦ ½Ç½ÃÇÏ¿© ¿µ»óÀ» º¸¸é¼ ÅÈÁÙ¼Ó¿¡ ¹Ù´ÃÀ» ³Ö¾î¼ ±×°÷ÀÇ Ç÷°üÀ» ã¾Æ Ç÷¾×À» äÃëÇÏ¿© °Ë»çÇÏ´Â ¹æ¹ý. 3)½ºÆ®·¹½º°Ë»ç-žƵµ Àڱüӿ¡¼ ¿îµ¿À» ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀ¸·Î žư¡ Àڱüӿ¡¼ ¿îµ¿À» ÇÒ °æ¿ì¿¡´Â žÆÀÇ ½ÉÀå ¹Úµ¿ÀÌ »¡¶óÁö°Ô µÈ´Ù. žÆÀÇ ¿îµ¿°ú žÆÀÇ ½ÉÀå¹Úµ¿À» µ¿½Ã¿¡ °¨½ÃÇÏ¿© ¿îµ¿½Ã¿¡ žÆÀÇ ½ÉÀå¹Úµ¿ÀÌ »¡¶óÁö´Â °¡¸¦ ¾Ë¾Æº¸´Â °ÍÀÌ´Ù. 4)žÆÃ»°¢Àڱذ˻ç-30ÁÖ ÀÌ»óÀÌ µÈ žƴ ¼Ò¸®ÀÇ Àڱؿ¡ ´ëÇØ¼ ¹ÝÀÀÀ» ÇÑ´Ù. Áï ¼Ò¸®¸¦ µé·ÁÁÖ¾úÀ» °æ¿ì¿¡ žư¡ ¹ÝÀÀÀ» ÇØ¼ ½ÉÀåÀÇ ¹Úµ¿¼ö°¡ Áõ°¡¸¦ ÇÑ´Ù. 5)¼öÃེƮ·¹½º°Ë»ç-Á¤»óÀûÀΠžƴ ÀÚ±ÃÀÌ ¼öÃàÇϸé ÀÌ¿¡ ¹ÝÀÀÀ» ÇØ¼ ½É¹Ú¼ö°¡ º¯ÈÇÑ´Ù. À̰ÍÀ» ÀÌ¿ëÇÏ¿© žÆÀÇ »óŸ¦ °Ë»çÇÏ´Â ¹æ¹ýÀÌ´Ù. 2. ºÐ¸¸Áß Å¾ư¨½Ã ºÐ¸¸µµÁß¿¡ žÆÀÇ °Ç°»óŸ¦ °¨½ÃÇÏ´Â °ÍÀÌ´Ù. ´ëü·Î ºÐ¸¸µµÁß¿¡ žư¡ Àú»ê¼ÒÁõÀ̳ª ¿©·¯ °¡Áö Ãæ°ÝÀ» ¹Þ´Â °æ¿ì°¡ ¸¹À¸¹Ç·Î ºÐ¸¸µµÁßÀÇ Å¾ư¨½Ã´Â Áß¿äÇÑ Àǹ̸¦ °¡Áø´Ù. 1)ÀüÀڽĞư¨½Ã-Àü±âÀû ÀåÄ¡¸¦ ÀÌ¿ëÇÏ¿© žÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ¸·Î °¨½ÃÀÇ ´ë»óÀº ÀÚ±ÃÀÇ ¼öÃà°ú žÆÀÇ ½ÉÀå¹Úµ¿¼öÀÌ´Ù. 2)žƸӸ®µ¤°³ Ç¥º»Ã¤Ãë Ç÷¾×-ºÐ¸¸µµÁß¿¡ žÆÀÇ µÎÇÇÀÇ Ç÷°ü¿¡¼ Ç÷¾×À» äÃëÇÏ¿© °Ë»ç¸¦ ÅëÇØ¼ žÆÀÇ »óŸ¦ ¾Æ´Â ¹æ¹ýÀÌ´Ù. ÁÖ·Î °Ë»ç¸¦ ÇàÇÏ´Â Á¾¸ñÀº Ç÷¾×ÀÇ pHÀÌ´Ù. |
||
| ¿µ¹® | heparin | ÇÑ±Û | ÇìÆÄ¸° |
|---|---|---|---|
| ¼³¸í | Ç÷¾× ÀÀ°í¸¦ ¸·´Â ÀÛ¿ëÀ» ÇÏ´Â ´Ù´ç·ùÀÇ È²»ê¿¡½ºÅ׸£. °íµîµ¿¹°ÀÇ °¢Á¾ Á¶Á÷¿¡ ³Î¸® ºÐÆ÷µÇ¾î ÀÖÀ¸¸ç, ¼ö¼ú ÈÄÀÇ Ç÷ÀüÁõÀ» ¸·´Â µ¥ ¾´´Ù. Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò´Â ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. ÀÌ ¼¶À¯¼Ò´Â Æ®·Òºó¿¡ ÀÇÇØ ¼¶À¯¼Ò¿ø¿¡¼ ÀüȯµÈ´Ù. ÇìÆÄ¸°À̶ó´Â ¹°ÁúÀº ÀÌ Æ®·ÒºóÀ» ¾ïÁ¦ÇÏ´Â Çׯ®·ÒºóÀ» Ȱ¼ºÈÇÏ´Â ¹°ÁúÀÌ´Ù. |
||
| ¿µ¹® | family therapy | ÇÑ±Û | °¡Á·¿ä¹ý |
|---|---|---|---|
| ¼³¸í | °¡Á·À» Ä¡·á ´ë»óÀ¸·Î ÇÏ´Â ½É¸®¿ä¹ý ÁßÀÇ Çϳª. °¡Á·ÁßÀÇ ¹®Á¦´Â ¹®Á¦¸¦ °¡Áø °³Àθ¸ÀÌ ¾Æ´Ï¶ó ¹®Á¦ °¡Á·À» ´ë»óÀ¸·Î ÇØ°áÇØ ³ª°¥ Çʿ䰡 ÀÖ´Ù´Â ÀνÄÀ» ¹ÙÅÁÀ¸·Î ÇÏ¿© °¡Á· ÀüüÀÇ ½É¸®Àû ¼º¼÷À» ¸ñÇ¥·Î ÇÑ ¿ä¹ýÀÌ´Ù. Å©°Ô ³ª´©¾î °¡Á· ÁßÀÇ Æ¯Á¤ÀÎÀ» ´ë»óÀ¸·Î ÇÏ¿© °¢°¢ ´Ù¸¥ µ¶¸³µÈ Ä¡·á¸¦ ÇÏ´Â º´Çà½É¸®¿ä¹ý°ú °¡Á· Àüü¸¦ µ¿½Ã ¸éÁ¢ÇÏ´Â ¹æ¹ýÀ» ÁÖ·Î ÇÏ´Â ÇÕµ¿°¡Á·¿ä¹ýÀÌ Àִµ¥, ƯÈ÷ ÈÄÀÚ¸¦ °¡¸®ÄÑ °¡Á·¿ä¹ý À̶ó°í ÇÏ´Â °æ¿ì°¡ ¸¹´Ù. |
||
| ¿µ¹® | intracavitary therapy | ÇÑ±Û | °³»¿ä¹ý |
|---|---|---|---|
| ¼³¸í | ü°³», Áï ÀÔ¾È, ÄÚ¾È, Àεΰ, ½Äµµ, °ðâÀÚ, Áú, Àڱøñ, ¹æ±¤ µîÀÇ ³»°¿¡, ¶§·Î´Â º´ÅÍ¿¡ ÀÇÇØ »ý±ä °øµ¿³»¿¡ ¹æ»ç¼±À» »ðÀÔÇØ¼ Ä¡·áÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. ÁÖ·Î Á¾¾çÀÇ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÑ´Ù. |
||
| ¿µ¹® | hyperbaric oxygenation therapy | ÇÑ±Û | °í¾Ð»ê¼Ò¿ä¹ý |
|---|---|---|---|
| ¼³¸í | ´ë±â¾Ðº¸´Ù ³ôÀº ±â¾Ðȯ°æÀ» ÀΰøÀûÀ¸·Î ¸¸µé¾î ±× ¾È¿¡¼ °í³óµµÀÇ »ê¼Ò¸¦ ÈíÀÔ½ÃŰ´Â ¿ä¹ý. Çѱ¹¿¡¼ ¿¬Åº°¡½º·Î ´ëÇ¥µÇ´Â ÀÏ»êÈź¼ÒÀÇ ±Þ¼ºÁßµ¶ÀÇ Ä¡·á¿¡ ¸¹ÀÌ ÀÌ¿ëµÈ °ÍÀ¸·Î, º¸Åë 3´ë±â¾Ð Á¤µµ·Î °¡¾ÐµÈ °í¾Ð»ê¼Ò½ÇÀ̳ª °í¾Ð»ê¼ÒÅÊÅ© ¼Ó¿¡ ȯÀÚ¸¦ ³õ°í Àü½Å¿¡ »ê¼Ò¸¦ ÈíÀÔ½ÃŲ´Ù. °í¾Ð½ÇÀº Å©°í ÀÛÀº ¿©·¯ °¡Áö°¡ ÀÖÀ¸¸ç, ±¸Á¶»ó 1½Ç½Ä-2½Ç½Ä-´Ù½Ç½ÄÀÌ ÀÖ´Ù. °¡¾Ð °¡½ºÀÇ Á¾·ù¿¡´Â »ê¼Ò-°ø±â-È¥ÇÕ °¡½ºµîÀÌ ÀÖ°í, 2~3 ´ë±â¾Ð ¶Ç´Â ±× ÀÌ»óÀÇ °í¾Ð ȯ°æÀ» ¸¸µç´Ù. ÀÓ»óÀûÀ¸·Î ÀÀ¿ë¹üÀ§°¡ ³Ð¾î¼ ±â°èÀû È¿°ú¿¡ ÀÇÇÏ¿© Àá¼öºÎº´À̳ª âÀÚ°ü¸¶ºñ¿¡ ÀÇÇÑ Ã¢ÀÚÆó»ö Ä¡·á µî¿¡ À¯È¿Çϰí, °¡½º±ËÀú µîÀÇ ¹«»ê¼Ò¼º ¼¼±Õ°¨¿°¿¡¼µµ ÀÌ¿ëµÈ´Ù. ¶Ç »ê¼Ò¿î¹ÝÈ¿°ú¿¡ ÀÇÇÏ¿© ÀÏ»êÈź¼Ò-½É±Ù°æ»ö-³ú»öÀüÁõ-ÃâÇ÷¼îÅ©¿¡ ÀÇÇÑ ±Þ¼ºÀÇ Á¶Á÷»ê¼Ò°áÇÌÀÇ Ä¡·á¿¡ À¯È¿ÇÏ´Ù. ¶Ç ¾ÏÀÇ ¹æ»ç¼±¿ä¹ý¿¡ º´¿ëÇϸé ÀÌ ¿ä¹ýÀ¸·Î ¾Ï¼¼Æ÷ÀÇ ºÐ¿ÀÌ ¿Õ¼ºÇØÁ®, ¼¼Æ÷ºÐ¿ ÁßÀÎ ¼¼Æ÷¿¡ ¹æ»ç¼±À» Á¶»çÇÔÀ¸·Î½á ºÐ¿´É·ÂÀ» ¾ø¾Ö´Â µ¥ À¯È¿ÇÏ¿© °í¾Ð»ê¼ÒÈíÀÔÁ¶»ç¹ýÀ̶ó°í ÇÑ´Ù. |
||
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
|---|---|
| IT | immunological test; immunotherapy; implantation test; individual therapy; information technology; in... |
| MT | magnetization transfer; malaria therapy; malignant teratoma; mammary tumor; mammilothalamic tract; m... |
| GT | gait training; galactosyl transferase; gastrostomy; generation time; genetic therapy; gingiva treatm... |
| RT | radiologic technologist; radiotelemetry; radiotherapy; radium therapy; rapid tranquilization; reacti... |
| LMW heparin | Low Molecular Weight heparin |
|---|---|
| ABPM | Ambulatory BP monitoring |
| ABPM | Ambulatory Blood Pressure Monitoring |
| AEM | Ambulatory Electrocardiographic Monitoring |
| AIMS | Australian Incident Monitoring Study |
| heparin | <drug> Sulphated mucopolysaccharide, found in granules of mast cells, that inhibits the action of thrombin on fibrinogen by potentiating antithrombins, thereby interfering with the blood clotting cascade. Platelet factor IV will neutralise heparin. (18 Nov 1997) |
|---|---|
| heparin antagonists | Coagulant substances inhibiting the anticoagulant action of heparin. (12 Dec 1998) |
| heparin binding growth factor | <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells. Synonym: heparin binding growth factor. Acronym: FGF (18 Nov 1997) |
| heparin cofactor II | <chemical> A sulfated plasma protein with the mw of approximately 66kda. The protein is an inhibitor of thrombin in plasma that is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily. Pharmacological action: serine proteinase inhibitors. Chemical name: Heparin cofactor II (12 Dec 1998) |
| heparin complement | The protein component of heparin in blood. (05 Mar 2000) |
| heparin eliminase | <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends. Chemical name: heparin lyase Registry number: EC 4.2.2.7 (12 Dec 1998) |
| heparin-glucosamine 3-O-sulfotransferase | <enzyme> Reaction: 3'-phosphoadenylylsulfate + heparin-glucosamine = adenosine 3',5'-bisphosphate + heparin glucosamine 3-o-sulfate Registry number: EC 2.8.2.23 Synonym: glucosaminyl 3-o-sulfotransferase, d-glucosaminyl 3-o-sulfotransferase (26 Jun 1999) |
| heparin, low-molecular-weight | <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. Pharmacological action: anticoagulant, fibrinolytic agent. (12 Dec 1998) |
| heparin lyase | <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends. Chemical name: heparin lyase Registry number: EC 4.2.2.7 (12 Dec 1998) |
| heparin unit | The quantity of heparin required to keep 1 ml of cat's blood fluid for 24 hr at 0°C; it is equivalent approximately to 0.002 mg of pure heparin. Synonym: Howell unit. (05 Mar 2000) |
| biological monitoring | This is the periodic examination of biological specimens for the purposes of monitoring their exposure to or the effects of potentially toxic chemicals to the environment. This is normally done by analysing the amounts of the toxic substances or their metabolites present in body tissues and fluids. The term is also used to mean assessment of the biological status of populations and communities of organisms at risk, in order to protect them and to gain an early warning of possible hazards to human health. (09 Oct 1997) |
| blood gas monitoring, transcutaneous | The noninvasive measurement or determination of the partial pressure (tension) of oxygen and/or carbon dioxide locally in the capillaries of a tissue by the application to the skin of a special set of electrodes. These electrodes contain photoelectric sensors capable of picking up the specific wavelengths of radiation emitted by oxygenated versus reduced haemoglobin. (12 Dec 1998) |
| blood glucose monitoring | A way of testing how much glucose (sugar) is in the blood. A drop of blood, usually taken from the fingertip, is placed on the end of a specially coated strip, called a testing strip. The strip has a chemical on it that makes it change colour according to how much glucose is in the blood. A person can tell if the level of glucose is low, high, or normal in one of two ways. The first is by comparing the colour on the end of the strip to a colour chart that is printed on the side of the test strip container. The second is by inserting the strip into a small machine, called a meter, which reads the strip and shows the level of blood glucose in a digital window display. Blood testing is more accurate than urine testing in monitoring blood glucose levels because it shows what the current level of glucose is, rather than what the level was an hour or so previously. (09 Oct 1997) |
| blood glucose self-monitoring | Self evaluation of whole blood glucose levels outside the clinical laboratory. A digital or battery-operated reflectance meter may be used. It has wide application in controlling unstable insulin-dependent diabetes. (12 Dec 1998) |
| blood pressure monitoring, ambulatory | Method in which prolonged blood pressure readings are made while the patient undergoes normal daily activities. It allows quantitative analysis of the high blood pressure load over time, can help distinguish between types of hypertension, and can assess the effectiveness of antihypertensive therapy. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|